Regeneron Pharmaceuticals Sued for Securities Law Violations
DJS Law Group has notified investors of a class action lawsuit filed against Regeneron Pharmaceuticals, Inc. concerning alleged violations of securities laws.
The DJS Law Group is alerting investors to a class action lawsuit that has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit alleges that the company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
According to the complaint, Regeneron allegedly made false and misleading statements to investors regarding its business, continuity, and/or future prospects. These statements are understood to pertain to the company's medical advancements and business valuations.
Investors who purchased Regeneron stock within a specified period may be eligible to participate in the lawsuit or a potential settlement. The DJS Law Group urges affected investors to contact the firm to learn more about their rights and potential actions.
The litigation is ongoing. Further details regarding the filed complaint and its specifics are available through the law group.